期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢透明细胞腺癌的DNA损伤应答反应 被引量：5

DNA Damage Response in Ovarian Clear Cell Adenocarcinoma
原文传递
导出
摘要 目的研究卵巢透明细胞腺癌的发生与DNA损伤应答之间的关系。方法对14例新鲜卵巢组织标本(正常卵巢组织3例,低分化卵巢肿瘤6例,透明细胞腺癌5例),采用X射线(2Gy)照射制备组织DNA损伤模型,分别对其进行组织冷冻切片,采用免疫荧光和Western免疫印迹方法检测DNA损伤应答反应。结果在X射线照射前,与正常卵巢组织细胞相比,透明细胞腺癌中存在大量内源性DNA损伤,X射线照射后组蛋白2A变体(H2AX)表现过度磷酸化,而损伤修复能力正常。p53结合蛋白1(53BP1)的激活与磷酸化的H2AX(γH2AX)不能共定位。结论卵巢透明细胞腺癌中DNA损伤异常激活,提示DNA损伤应答信号转导网络存在缺陷。 Objective To study the relationship between ovarian clear cell adenocarcinoma and DNA damage.Methods 14 samples were selected from clinical ovaian cases including 3 cases with normal ovarian tissue,6 cases with poorly differentiated ovarian tumor,5 cases with ovarian clear cell adenocarcinoma,treated by X-ray irradiation and frozen sections respectively.DNA damage response was analyzed by immunofluorescence and Western blot.Results Before X-ray irradiation,compared to normal ovarian tissue,a large number of endogenous damage existed in ovarian clear cell adenocarcinoma,and phosphorylation of histone family 2A variant(H2AX) was abnormally enhanced 1 hour after irradiation treatment,however,DNA repair was normal in ovarian clear cell adenocarcinoma.Phosphorylation of H2AX was dispensable for p53 binding protein l(53BP1) activation and couldn't be colocalized in clear-type ovarian cancer tissues.Conclusion The abnormal DNA damage activation implies that the network of DNA damage signaling pathway may be defective.
作者 贾月改 杨月明 左斌 郭莲娣 楼江燕
机构地区 四川大学华西第二医院妇产科 四川大学华西第二医院发育与干细胞研究所
出处 《四川大学学报（医学版）》 CAS CSCD 北大核心 2012年第3期331-334,共4页 Journal of Sichuan University(Medical Sciences)
关键词 透明细胞腺癌 DNA损伤 磷酸化组蛋白2A变体 p53结合蛋白1 Ovarian clear cell adenocarcinoma DNA damage γH2AX 53BP1
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Sugiyama T,Kamura T,Kigawa J,et al.Clinicalcharacteristics of clear cell carcinoma of the ovary:a distincthistologic type with poorprognosis and resistance to platinum-based chemotherapy.Cancer,2000;88(11):2584-2589.
  • 2Takano M,Kikuchi Y,Yaegashi N,et al.Clear cell carcinomaof the ovary:a retrospective multicentre experience of 254patients with complete sorgical staging.Br J Cancer,2006;94(10):1369-1374.
  • 3Chan JK,Teoh D,Hu JM,et al.Do clear cell ovariancarcinomas have poorer prognosis compared to other epithelialcell types A study of 1411clear cell ovarian cancers.GynecolOncol,2008;109(3):370-376.
  • 4Rouse J,Jackson SP.Interfaces between the detection,signaling,and repair of DNA damage.Science,2000;2297(5581):547-551.
  • 5Fernandez-Capetillo O,Celeste A,Nussenzweig A.Focusingon foci:H2AX and the recruitment of DNA-damage responsefactors.Cell Cycle,2003;2(5):426-427.
  • 6Paull TT,Rogakou EP,Yamazaki V,et al.A critical role forhistone H2AX in recruitment of repair factors to nuclear fociafter DNA damage.Curr Biol,2000;10(15):886-895.
  • 7Celeste A,Fernandez-Capetillo O,Kruhlak MJ,et al.HistoneH2AX phosphorylation is dispensable for the initial recognitionof DNA breaks.Nat Cell Biol,2003;5(7):675-679.
  • 8Swenberg JA,Lu K,Benjamin C,et al.Endogenous versusexogenous DNA adducts:their role in carcinogenesis,epidemiology,and risk assessment.Toxicol Sci,2011;120(Suppl 1):S130-145.
  • 9Laiho M,Latonen L.Cell cycle control,DNA damagecheckpoints and cancer.Ann Med,2003;35(6):391-397.
  • 10Bartek J,Bartkova J,Lukas J.DNA damage signalling guardsagainst activated oncogenes and tumour progression.Oncogene,2007;26(56):7773-7779.

同被引文献81

  • 1Fasching PA, Gayther S, Pearce L, et al. Role of genetic pol- ymorphisms and ovarian cancer susceptibility [J] . Mol On- col, 2009, 3 (2): 171-181.
  • 2Swenberg JA, Lu K, Benjamin C, et al. Endogenous versus exogenous DNA adducts: their role in carcinogenesis epidemi- ology, and risk assessment [J] . Toxicol Sci, 2011, 120 ( Suppl 1 ) : S130 - S145.
  • 3Metivier R, Gallais R, Tiffoche C, et al. Cyclical DNA meth- ylation of a transcriptionally active promoter [ J ] . Nature, 2008, 452 (7183): 45-50.
  • 4Asadollahi R, Hyde AC, Zhong XY. Epigenetics of ovarian cancer: from the lab to the clinic [J] . Gynecol Oncol, 2010, 118 (1): 81-87.
  • 5Mchaelson R, Keshet I, Straussman R, et al. Genome - wide denovo methylation in epithelial ovarian cancer [J] . Int J Gy- necol Cancer, 2011, 21 (2): 269-279.
  • 6Watts GS, Futscher BW, Holtan N, et al. DNA methylation changes in ovarian cancer are cumulative with disease progres- sion and identify tumor stage [J] . BMC Med Genomics, 2008, 1 (1): 47.
  • 7Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinum - based chem- otherapy in epithelial ovarian cancer [ J ] . Cancer Invest, 2009, 27 (8): 877-884.
  • 8Ma L, Guo Q, Ma Y, et al. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancer [J] . Eur J Gynaecol Oncol, 2009, 30 (4) : 370 -374.
  • 9Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer [J] . Dis Markers, 2007, 23 (1/ 2) : 73 -87.
  • 10Kimura S, Naganuma S, Susuki D, et al. Expression of mi- croRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR- 205 and miR- 21 are specific markers for HNSCC and ESCC [J] . Oneol Rep, 2010, 23 (6) : 1625 - 1633.

引证文献5

二级引证文献6

四川大学学报（医学版）
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部